Ai Qing-Hua, Li Yuan-Yuan, Xie Yan-Ming
Zhongguo Zhong Yao Za Zhi. 2014 Sep;39(18):3633-6.
In order to promote the Shenqifuzheng injection (SQFZ) clinical medication safety, this study reevaluate on SQFZ post marketing safety study systematically. Including multi center large sample registration type safety monitoring research, the analysis based on national spontaneous reporting system data, the analysis based on the 20 national hospital information system data and literature research. Above the analysis, it suggests that SQFZ has good security. The more adverse drug reaction (ADR) as allergic reactions, mainly involved in the damage of skin, appendages and its systemic damage, serious person can appear allergic shock. ADR/E is more common in the elderly, may be related to medication (tumor) populations. Early warning analysis based on SRS data and literature research are of the view that "phlebitis" has a strong association with SQFZ used.
为促进参芪扶正注射液(SQFZ)临床用药安全,本研究对SQFZ上市后安全性进行系统再评价。包括多中心大样本注册型安全性监测研究、基于国家自发报告系统数据的分析、基于全国20家医院信息系统数据的分析以及文献研究。综合上述分析表明,SQFZ安全性良好。药物不良反应(ADR)以过敏反应较多,主要累及皮肤及其附属器损害和全身性损害,严重者可出现过敏性休克。ADR/E在老年人中较为常见,可能与用药(肿瘤)人群有关。基于自发报告系统(SRS)数据和文献研究的预警分析认为,“静脉炎”与SQFZ使用有较强关联。